To access the full text documents, please follow this link: http://hdl.handle.net/2445/124033

Pseudoprogression as an adverse event of glioblastoma therapy
Balaña, Carmen; Capellades, Jaume; Pineda, Estela; Estival, Anna; Puig, Josep; Domenech, Sira; Verger, Eugènia; Pujol, Teresa; Martínez García, Maria; Oleaga Zufiría, Laura; Velarde, Jose Maria; Mesia Barroso, Carlos; Fuentes, Rafael; Marruecos, Jordi; Barco, Sonia Del; Villà, Salvador; Carrato, Cristina; Gallego, Oscar; Gil Gil, Miguel; Craven Bartle, Jordi; Alameda, Francesc; GLIOCAT Group
We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and basal imaging characteristics and compared overall survival (OS), progression-free survival (PFS), post-progression survival (PPS) as well as the relationship between PFS and PPS in the three groups. Of the 256 patients studied, 56 (21.9%) were classified as PsP, 70 (27.3%) as eP, and 130 (50.8%) as nP. Only MGMT methylation status was associated to PsP. MGMT methylated patients had a 3.5-fold greater possibility of having PsP than eP (OR: 3.48; 95% CI: 1.606-7.564; P=0.002). OS was longer for PsP than eP patients (18.9 vs. 12.3months; P=0.0001) but was similar for PsP and nP patients (P=0.91). OS was shorter-though not significantly sofor PsP than nP patients (OS: 19.5 vs. 27.9months; P=0.63) in methylated patients. PPS was similar for patients having PsP, eP or nP (PPS: 7.2 vs. 5.4 vs. 6.7; P=0.43). Neurological deterioration occurred in 64.3% of cases at the time they were classified as PsP and in 72.8% of cases of eP (P=0.14). PsP confounds the evaluation of disease and does not confer a survival advantage in glioblastoma.
-Tumors cerebrals
-Brain tumors
cc by (c) Balaña et al., 2017
http://creativecommons.org/licenses/by/3.0/es/
Article
Article - Published version
Wiley
         

Show full item record

Related documents

Other documents of the same author

Esteve Codina, Anna; Arpi, Oriol; Martínez-García, María; Pineda, Estela; Mallo, Mar; Gut, Marta; Carrato, Cristina; Rovira, Anna; López, Raquel; Tortosa i Moreno, Avelina; Dabad, Marc; Barco, Sonia del; Heath, Simon C.; Bagué, Silvia; Ribalta Farrés, Teresa María; Alameda, Francesc; Iglesia, Núria de la; Balaña, Carmen; GLIOCAT Group
Esteve Codina, Anna; Arpi, Oriol; Martínez-García, María; Pineda, Estela; Mallo, Mar; Gut, Marta; Carrato, Cristina; Rovira, Anna; López, Raquel; Tortosa i Moreno, Avelina; Dabad, Marc; Barco, Sonia del; Heath, Simon; Bagué, Silvia; Ribalta Farrés, Teresa María; Alameda, Francesc; Iglesia, Núria de la; Balaña, Carmen; GLIOCAT Group
Esteve-Codina, Anna; Arpí Llucià, Oriol; Martínez-García, Maria; Pineda, Estela; Mallo, Mar; Gut, Marta; Carrato, Cristina; Rovira Guerín, Ana; Lopez, Raquel; Tortosa, Avelina; Dabad, Marc; Del Barco, Sonia; Heath, Simon; Bagué, Silvia; Ribalta, Teresa; Alameda Quitllet, Francisco; de la Iglesia, Nuria; Balaña, Carmen; GLIOCAT Group
Molina, David; Pérez Beteta, Julián; Martínez González, Alicia; Sepúlveda, Juan M.; Peralta, Sergi; Gil Gil, Miguel; Reynes, Gaspar; Herrero, Ana; Peñas, Ramón De Las; Luque, Raquel; Capellades, Jaume; Balaña, Carmen; Pérez García, Víctor M.
Esteve-Codina, Anna; Arpi, Oriol; Martinez-García, Maria; Pineda, Estela; Mallo, Mar; Gut, Marta; Carrato, Cristina; Rovira, Anna; Lopez, Raquel; Tortosa, Avelina; Dabad, Marc; Del Barco, Sonia; Heath, Simon; Bagué, Silvia; Ribalta, Teresa; Alameda, Francesc; de la Iglesia, Nuria; Balañá, Carmen; on behalf of the GLIOCAT Group; Glioma Catalonia Group (GLIOCAT); Universitat Autònoma de Barcelona
 

Coordination

 

Supporters